Navigation Links
The Downside of Asthma Medication

Could a common class of drugs used for acute asthma attacks be causing the very thing it aims to treat?//

Perhaps, find researchers from Harvard School of Public Health and Brigham and Women’s Hospital who studied the use of bronchodilators known as beta-agonists in asthmatics.

Beta-agonists are the primary treatment used to relieve acute asthma attacks. The drugs come in many forms -- they may be delivered with an inhaler, given in pill or liquid form, delivered in a nebulizer, or given by injection. Whatever the mode of administration, they work by relaxing the airway and reducing airway responsiveness to allergens that cause it to restrict and cause an acute attack. Many people with asthma rely heavily on these medications, sometimes taking them several times a day. Previous research suggests regular use could increase sensitivity to airway constriction and thus lead to a greater number of attacks and more serious attacks, primarily by causing a desensitization of the beta2-adrenergic receptor (beta2AR) that the drug binds with to achieve its effects.

These researchers suggest an alternative mechanism. Their study finds the increased airway hyperresponsiveness seen in some regular users of beta-2 agonists may be due to increased expression of a substance called phospholipase C-beta (PLC-beta) in the smooth airway muscle that occurs with persistent high-level activation of the beta2AR. The finding may lead to new treatments for asthma targeting PLC-beta.

Writing in an accompanying commentary, other researchers from Harvard and Brigham and Women’s concur, noting, “Understanding the panoply of beta2AR-mediated events in airway smooth muscle might lead to the design of new agonists that avoid negative effects of beta2AR activation while enhancing events that lead to relaxation.”

'"/>




Page: 1

Related medicine news :

1. Downside of Diets in Children
2. New Drug for Bronchial Asthma
3. Asthma may actually be prevented by Dust and Dirt
4. Inhaled Steroids Safe & Effective for Children with Asthma
5. What happens when Asthmatics consume Aspirin?
6. Asthma! A new warning for heart disease
7. Asthma linked to obesity
8. Higher Risk of Asthma in children with autoimmune disease
9. Asthmatics at increased risk of lung cancer
10. Cleanliness might lead to Asthma
11. Asthma is not just a childhood condition
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/12/2017)... WILMINGTON, Del. (PRWEB) , ... October 12, 2017 ... ... technology and advisory services for healthcare compliance program management, will showcase a range ... and National Association for Assisted Living (NCAL) Convention and Expo to be held ...
(Date:10/12/2017)... PALM CITY, Fla. (PRWEB) , ... October 12, 2017 , ... ... of cold therapy products, announced today the introduction of an innovative new design of ... the multipurpose pad so you get maximum comfort while controlling your pain while using ...
(Date:10/12/2017)... ANGELES (PRWEB) , ... October 12, 2017 , ... ... Parsa Mohebi Hair Restoration, has recently contributed a medical article to the newly ... on cosmetictown.com. Dr. Mohebi’s article spotlights the hair transplant procedure known as ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... one of Michigan’s 2017 Best and Brightest in Wellness® by Best and Brightest. ... awards program on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at ...
(Date:10/12/2017)... Washington, D.C. (PRWEB) , ... October 12, 2017 ... ... Company, Cal Dining at the University of California Berkeley, and other leading institutions ... leverages the buying power of institutions to change the way animals are raised ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... YORK , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a ... today announced that its MyDario product is expected to appear on The ... when The Dr. Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. Oz ... The ...
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, ... complete response letter from the U.S. Food and Drug ... approval of sirukumab for the treatment of moderately to ... indicates additional clinical data are needed to further evaluate ... to severely active RA. ...
(Date:9/19/2017)... -- HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy ... team developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D ...
Breaking Medicine Technology: